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Aim: To investigate the count of circulating tissue factor-positive (TF+) procoagulant
microparticles (MPs) in patients with type 1 diabetes mellitus (T1DM).
Methods: This case-control study included patients with T1DM and age and sex-matched
healthy volunteers. The counts of phosphatidylserine-positive (PS+) MPs and TF+PS+MPs and
the subgroups derived from different cell types were measured in the peripheral blood sample
of the two groups using multicolor ﬂow cytometric assay. We compared the counts of each MP
between groups as well as the ratio of the TF+PS+MPs and PS+MPs (TF+PS+MPs/PS+MPs).
Results: We recruited 36 patients with T1DM and 36 matched healthy controls. Compared
with healthy volunteers, PS+MPs, TF+PS+MPs and TF+PS+MPs/PS+MPs were elevated in
patients with T1DM (PS+MPs: 1078.5 ± 158.08 vs 686.84 ± 122.04/μL, P <0.001;
TF+PS+MPs: 202.10 ± 47.47 vs 108.33 ± 29.42/μL, P <0.001; and TF+PS+MPs/PS+MPs:
0.16 ± 0.04 vs 0.19 ± 0.05, P = 0.004), mostly derived from platelet, lymphocytes and
endothelial cells. In the subgroup analysis, the counts of total and platelet TF+PS+MPs were
increased in patients with diabetic retinopathy (DR) and with higher HbA1c, respectively.
Conclusion: Circulating TF+PS+MPs and those derived from platelet, lymphocytes and
endothelial cells were elevated in patients with T1DM.
Keywords: type 1 diabetes mellitus, microparticles, tissue factor, diabetic retinopathy
Introduction
Type 1 diabetes mellitus (T1DM) is a multifactorial autoimmune disease character-
ized by destruction of pancreatic beta cells.1 Patients with T1DM have to use
exogenous insulin replacement from diagnosis and face the risks of developing
micro- and macro-vascular complications, potentially leading to a poor quality of
life and premature mortality.2,3
Procoagulant microparticles (MPs) are heterogeneous populations of small vesicles
which express phosphatidylserine (PS) ranging in size from 0.1 to 1.0μm, which are
larger and more heterogeneous than exosomes (30 to 100nm).4 They can be released
from most types of cells including erythrocytes, platelets, lymphocytes and endothelial
cells during their activation, injury, or apoptosis.5 MPs are recognized multifunctional
structures containing proteins, genetic information and lipids, which facilitate cross-
talk between cells and regulate various pathological conditions such as coagulation,
vascular inﬂammation, endothelial dysfunction, angiogenesis, cell apoptosis and
immune response.6,7 Circulating MPs are reported to be elevated in diseases like
hypertension, stroke, coronary heart disease and metabolic syndrome.8–11
Accumulating data indicates that counts of MPs are increased both in diabetic animal
models and in diabetic patients.12–16 Our previous meta-analysis indicates that total
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MPs, platelet-derived MPs (PMPs), monocyte-derived MPs
(MMPs) and endothelium-derived MPs (EMPs) are signiﬁ-
cantly higher in patients with type 2 diabetes than those in
controls.17 MPs derived from platelets, monocytes, and
endothelial cells in diabetic patients with vascular complica-
tions are reported to be higher than in those without vascular
complications.18–22 Previous studies also indicated increased
counts of total MPs, PMPs and EMPs were in patients with
T1DM.18,23
The procoagulant activity of MPs is mainly driven by
the PS expression.24 The tissue factor (TF) present on the
procoagulant MPs (TF+PS+MPs) activates both Factor IX
(FIX) and Factor X (FX) to initiate coagulation by binding
Factor VII/Factor VIIa (FVII/FVIIa) as a receptor,25 which
greatly increases the procoagulant activity of PS+MPs.26
TF+PS+MPs facilitate the formation of thrombus by dou-
bling their counts and expressing thrombotic molecules in
a short time.27,28 Given the strong procoagulant activity of
TF+PS+MPs, we hypothesized that they may be elevated
as a consequence of developing T1DM diabetes and its
associated complications.
In this study, we aim to investigate the circulating
TF+PS+MPs and their subtypes derived from different
cell types in patients with T1DM and healthy volunteers
using multicolor ﬂow cytometric assay and explore the
potential association between TF+PS+MPs and the labora-
tory and clinical features.
Materials and Methods
Subjects
The T1DM patients and age and sex-matched healthy
volunteers were recruited separately in this case-control
study. The T1DM patients were from COntinuous
Management and Biomarker Study of type 1 diabetes
(COMBS-1) study, which is a single-center cohort study
of T1DM since 2015. The COMBS-1 study continuously
recruited patients with T1DM from the inpatient and out-
patient department in West China Hospital, Sichuan
University and peer groups for patients with diabetes
who met the following criteria: (1) diagnosis of T1DM
requires all the following criteria: a. meeting the criteria
for the diagnosis of diabetes mellitus according to WHO
1999 Criteria;29 b. with any overt diabetes-related symp-
toms when onset (ie, thirsty, polyuria, polydipsia, poly-
phagia or weight loss); c. with the history of diabetic
ketosis or ketoacidosis; d. needing long-term insulin treat-
ment from diagnosis; e. body mass index (BMI) ≤25Kg/m2
at the onset of diabetes; f. the age of onset is less than 30
years; (2) over 14 years of age when recruitment. The
exclusion criteria included: (1) known or conﬁrmed mito-
chondrial diabetes and monogenic diabetes; (2) life expec-
tancy shorter than 2 years; (3) patients with severe mental
disorders or patients who are unable to cooperate with the
follow-up; (4) pregnancy when recruitment; (5) patients
who are not willing to follow the study protocol. Previous
medical history data, vital signs, physical examinations
and questionnaires of each patient were collected at base-
line. Islet cell antibodies were not included in the recruit-
ment criteria for the study as Chinese patients display less
antibody positivity than Caucasian populations (reported
60.7% based on literature).30 In the current study, we
further exclude patients meeting the following criteria:
(1) overt vascular or hematological disease, thromboem-
bolic or coagulation disorders; (2) treatment with aspirin,
clopidogrel or anticoagulant drugs in the past four weeks.
Age- and sex- matched healthy volunteers were recruited
from the staffs and medical students in West China
Hospital during the study period, if they were free of self-
reported diabetes, hypertension, autoimmune disease,
acute or chronic inﬂammation or disease related to throm-
bosis and hemostasis. All subjects gave written informed
consent in accordance with local ethics committee recom-
mendations before study enrollment. The study protocol
was conducted in accordance with the Declaration of
Helsinki, was approved by the ethics committee of West
China Hospital, Sichuan University.
Laboratory Tests
Routine blood cell count was detected by automated
hematology analyzer. Fasting blood glucose (FBG),
total cholesterol (TC), triglycerides (TG), creatinine
were measured on an automatic biochemistry analyzer
(Modular P800, Roche Diagnostics GmbH, Germany)
according to standard laboratory procedures. HbA1c
was determined by a method based on high-
performance liquid chromatography (HPLC) which was
approved by the National Glycohemoglobin
Standardization Program (NGSP) (HLC-723 G8, Tosoh
Corporation, Japan). Urinary albumin and creatinine were
used to calculate urinary albumin-to-creatinine (UACR).
High-sensitivity C-reactive protein (hs-CRP) was mea-
sured by latex immunoturbidimetric method. Dilated ret-
inal photography was taken in all patients which were
reviewed by an ophthalmologist (Jiaying Zhang). The
diabetic retinopathy (DR) was diagnosed and graded
Zhang et al Dovepress
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based on the International Clinical Diabetic Retinopathy
and Macular Edema Disease Severity Scale.31
Isolation of Plasma MP
Blood was collected into sodium citrate tubes and was
centrifuged at 2500×g for 10 mins at 20°C. The super-
natant was then centrifuged again at 2500×g for 10 mins to
obtain platelet-free plasma (PFP). The samples were then
stored at −80°C until analysis.
Immunolabelling of MPs
After thawing, 5μL of PFP was diluted to 50μL with phos-
phate-buffered saline (PBS). The samples were incubated
with mAbs as follows in the dark for 30 mins at room
temperature. Annexin-V-APC and PE-conjugated mAb
against TF was used to mark total PS+MPs and TF+MPs,
respectively. FITC-conjugated mAb against platelet glyco-
protein GPIIbIII (FITC-CD41a) was used to label platelet-
derived MPs (PMPs). BV421-conjugated mAb CD235a was
used to identify red blood cell-derived MPs (RMPs). APC-
Cy7-conjugated mAb CD3 and PerCp-Cy5.5-conjugated
mAb CD20 were identiﬁed T lymphocytes-derived MPs
(TMPs) and B lymphocytes-derived MPs (BMPs), respec-
tively. PE-CF594-conjugated mAb against CD14 was used
to identify MMPs. PE-Cy7-conjugated mAb against VE-
Cadherin (CD144) and V510-conjugated mAb against
V-CAM1 (CD106) were used to identify EMPs. All reagents
were purchased at BD Bioscience (San Diego, CA, USA).
After incubation, 100μL of binding buffer was added. To
determine the concentrations of the TF+MPs, 5.0 μL Flow-
Count Fluorospheres (Beckman Coulter Immunotech, USA)
was added to each tube. Samples were then prepared for
ﬂow cytometric analysis.
Flow Cytometric Analysis
The prepared sampleswere detected using established protocol
in the FACSAria cytometer (Becton Dickinson, San Jose, CA,
USA) equipped with the FACS Diva 5.0 software and data
were analyzed by FlowJo 10 (Tree Star, Ashland, OR,USA).32
MPs were analyzed based on their parameters of size and
ﬂuorescence. Firstly, the upper and lower limits of the MPs
were determined on the size using 1.0μmcalibration beads and
0.1μm calibration beads (Nano Fluorescent Size Standard Kit,
Spherotech, USA). As shown in Figure 1, the events ranged in
this gate and combined with positive Annexin-V expression
(label for PS) were identiﬁed as procoagulant MPs (PS+MPs).
Secondly, different types of PS+MPs were further distin-
guished by surface markers from the originated cells. To
calculate the absolute value from each sample, ﬂow-count
ﬂuorosperes were introduced since the total number of micro-
spheres present in each sample was known. The count of MPs
was calculated using the following formula:
Absolute count of MPs Beads=μLð Þ
¼ Number of MPs counted Beads=μLð Þ
 Flow - count fluorosperes assayedMPs Beads=μLð Þ
Number of fluorosperes countedMPs Beads=μLð Þ
The ratio of TF+PS+MPs and PS+MPs (TF+PS+MPs/
PS+MPs) was calculated by dividing TF+PS+MPs by PS+MPs.
Statistical Analyses
Distribution of the data was tested by the Kolmogorov–
Smirnov test. Continuous variables were presented as
means ± standard deviations (SDs) when normally distribu-
ted or medians and ranges when not. Difference between
groups was analyzed by paired student’s t-test for comparing
normally distributed continuous data and Mann–Whitney
U-test for those non-normally distributed data. Pearson’s
correlation analysis and Spearman correlation analysis were
performed to assess the correlation betweenMPs and clinical
as well as laboratory variables among T1DM patients for
normally and non-normally distributed data, respectively.
Among the patients with T1DM, two subgroup analyses
were conducted based on the presentation of DR and glucose
control (HbA1c over or not over 7%). A 2-tailed p <0.05 was
considered as statistical signiﬁcant. Analyses were per-
formed with SPSS 19.0 (Spss, Inc., Chicago, IL).
Results
Clinical Characteristics
The ﬂowchart of patient recruitment is shown in Figure 1. We
included 36 patients with T1DM and 36 age and sex-matched
healthy volunteers in the study. The baseline characteristics of
T1DM patients and healthy controls are presented in Table 1.
The median age of T1DM patients was 23.5 (range from 16.0
to 46.0) years and 24 patients (67%) were females. The
median duration of diabetes was 4.8 (ranged from 0.1 to
26.8) years. All T1DM patients were treated with insulin,
however, 22 of 36 patients (61%) were noted to have an
HbA1c above 7%. As shown in Table 1, the waist-hip ratio
(WHR), TG, HbA1c, FBG, UACR and hs-CRPwere higher in
T1DM patients compared with healthy controls. There were
no signiﬁcant differences in age, blood pressure, blood cell
counts or total cholesterol between the two groups. DR was
identiﬁed in 16 (44%) of the T1DM patients, among which 15
of them had non-proliferative diabetic retinopathy (9 mild and
Dovepress Zhang et al
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6 moderate) and one had proliferative diabetic retinopathy.
None of the studied patients had albuminuria (deﬁned as
UACR >30 mg/g) or macro-vascular complications or cardi-
ovascular diseases.
Quantiﬁcation of PS+MPs in Two Groups
We identiﬁed the plasma MPs using ﬂow cytometry by
gating on particle size (ranging from 0.1μm to 1μm) with
positive annexin V and with speciﬁc antibodies (Figure 2).
As shown in Figure 3A, we found that the counts of total
PS+MPs in T1DM patients were elevated compared with
healthy controls (1078.5 ± 158.08 vs 686.84 ± 122.04/μL;
P < 0.001). There was increased counts of PMPs (409.47 ±
52.03 vs 211.18 ± 45.44/μL; P <0.001), TMPs (39.89 ± 7.19
vs 26.66 ± 8.71/μL; P <0.001) and BMPs (15.89 ± 3.57 vs
11.61 ± 5.18/μL; P <0.001) in T1DM patients compared to
the controls. The EMP levels identiﬁed by expression of
CD144 and CD105 were markedly elevated in the patients
with the T1DM compared with the controls (2.47 ± 1.59 vs
1.08 ± 0.61/μL; P <0.001). There were no signiﬁcant differ-
ences between T1DM patients and healthy controls in cir-
culating levels of RMPs (29.73 ± 9.82 vs 31.93 ± 8.86/μL;
P = 0.32) or MMPs (69.18 ± 10.05 vs 71.30 ± 12.45/μL;
P = 0.43).
Quantiﬁcation of TF+PS+MP in TwoGroups
As shown in Figure 3B, TF+PS+MP counts were greater for
the T1DM patients than healthy controls (202.10 ± 47.47 vs
108.33 ± 29.42/μL; P <0.001), mostly derived from platelets
(56.76 ± 15.95 vs 26.03 ± 6.30/μL; P <0.001), T cells (6.74 ±
2.81 vs 4.11 ± 1.81/μL; P <0.001), B cells (2.62 ± 1.24 vs 2.05
± 0.99/uL; P = 0.034) and endothelial cells [0.72 (0.27–2.83)
vs 0.50 (0.00–1.10), P <0.001]. The TF+PS+MPs/PS+MPs
were also elevated in the T1DM patients (0.16 ± 0.04 vs
0.19 ± 0.05, P = 0.004, Figure 3C). However, none of the
ratios of cell-origin speciﬁc TF+PS+MPs were statistically
signiﬁcant. There were no signiﬁcant differences between
T1DM patients and healthy controls in TF+PS+MPs derived
from erythrocytes (10.31 ± 2.93 vs 9.84 ± 2.69/μL, P = 0.47)
or monocytes (17.86 ± 4.42 vs 16.73 ± 4.54/μL, P = 0.28).
Subgroup Analysis of MPs in Patients with
T1DM
T1DM patients were divided into two groups based on
the presence of DR. As presented in Table 2, patients
Department of Endocrinology and Metabolism 
(Sep 2015 to May 2016)
- The outpatient Department (n = 20) 
- The inpatient Department (n = 65) 
The peer group of T1DM 
in West China Hospital 
(n = 55)
Enrolled in T1DM patients cohort 
(n = 40)
Fitting the inclusion and exclusion 
criteria of COMBS-1 
Accorded with the exclusion
criteria of this study 
4 patients were excluded
- Anemia (n = 2)
- Pregnancy (n = 2) 
Included for the analysis of MPs
(n = 36)
Figure 1 Flowchart of T1DM patient enrollment.
Table 1 Clinical Characteristic of Patients with T1DM and Healthy
Controls. Data are Presented as Means ± Standard Deviations
(SDs) or Medians (Ranges)
Variable T1DM Healthy
Control
P value
N 36 36 –
Male/Female 12/24 12/24 –
Median age (yrs) 23.5 (16.0–46.0) 24.5 (19.0–45.0) 0.197
Duration of diabetes (yrs) 4.8 (0.1–26.8) – –
BMI (kg/m2) 21.2 ± 2.3 20.6 ± 1.8 0.640
WHR 0.88 ± 0.05 0.84 ± 0.05 0.001
SBP (mmHg)
DBP (mmHg)
107.9 ± 8.4
67.2 ± 7.1
111.5 ± 7.3
69.6 ± 7.0
0.056
0.146
RBC (×1012/L) 4.5 ± 0.5 4.4 ± 0.5 0.254
WBC (×109/L) 5.7 ± 1.7 5.8 ± 1.6 0.711
Neutrophilia (×109/L) 3.0 ± 0.8 3.5 ± 1.3 0.096
Lymphocyte (×109/L) 1.8 ± 0.5 1.7 ± 0.4 0.639
Platelet (×109/L) 182.0 ± 61.2 208.0 ± 49.5 0.076
Total cholesterol (mmol/L) 4.62 ± 1.0 4.30 ± 0.76 0.137
LDL-C (mmol/L) 2.43 ± 0.71 2.23 ± 0.68 0.231
HDL-C (mmol/L) 1.64 ± 0.44 1.58 ± 0.33 0.459
Triglycerides (mmol/L) 1.01 ± 0.46 0.85 ± 0.39 0.053
FBG (mmol/L) 11.40 ± 4.72 4.65 ± 0.45 <0.001
HbA1c (%) 8.58 ± 2.43 4.98 ± 0.34 <0.001
Serum creatinine (umol/L) 60.7 ± 11.5 61.0 ± 10.0 0.944
UACR 6.60 (2.60–23.05) 5.55 (2.80–8.80) 0.020
hs-CRP (mg/dL) 1.21 ± 0.50 0.28 ± 0.13 <0.001
Diabetic retinopathy 16/36 - -
NPDR 15/16 - -
PDR 1/16 - -
Abbreviations: T1DM, type 1 diabetes mellitus; BMI, body mass index; WHR,
waist-hip-ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; RBC,
red blood count; WBC, white blood count; LDL-C, low-density lipoprotein cho-
lesterol; HDL-C, high-density lipoprotein cholesterol; FBG, fasting blood glucose;
HbA1c, glycated hemoglobin; UACR, urinary albumin-to-creatinine ratio; hs-CRP,
highly sensitive C-reactive protein; NPDR, non-proliferative diabetic retinopathy;
PDR, proliferative diabetic retinopathy
Zhang et al Dovepress
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with DR had a greater concentration of TF+PS+MP than
those without DR (P <0.001). There were no differences
between these two groups in PS+MPs, and other types of
TF+PS+MPs. Subgroup analysis stratiﬁed HbA1c was
also performed in patients with T1DM. Patients with
HbA1c higher than 7% had a greater count of
TF+PS+MPs derived from platelet than those with
HbA1c less than 7% (P <0.001).
Figure 2 Quantitative detection of PS+MPs and TF+PS+MPs by Flow cytometry. Quantitative detection of PS+MPs and TF+PS+MPs by Flow cytometry. (A) Events ranged
from 0.1μm to 1μm in size using Nano Fluorescent Size Standards; (B) Events ranged from 0.1 μm to 1.0 μm and binding annexin V were considered as PS+MPs; (C) Flow-
Count Fluorospheres were gated on BV421/PE-Cy7 dot plot; (D) Gate of PS+MPs derived from platelets and erythrocytes (PS+PMPs and PS+RMPs, respectively); (E) Gate of
PS+MPs derived from T cells and B cells (PS+TMPs and PS+BMPs, respectively); (F) Gate of PS+MPs derived from monocytes (PS+MMP); (G) Gate of PS+MPs derived from
endothelium cells (PS+EMPs); (H) Gate of TF+PS+RMPs; (I) Gate of TF+PS+PMPs; (J) Gate of TF+PS+BMPs; (K) Gate of TF+PS+TMPs; (L) Gate of TF+PS+MMPs; (M) Gate of
TF+PS+EMPs.
Dovepress Zhang et al
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2019:12 submit your manuscript | www.dovepress.com
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Figure 3 The counts of PS+MPs and TF+PS+MPs in T1DM patients and healthy controls. (A). Flow cytometry analysis of PS+MPs in T1DM patients and healthy controls. (a)
total PS+MPs; (b) PMPs; (c) RMPs; (d) TMPs; (e) BMPs; (f) MMPs and (g) EMPs. (B) Flow cytometry analysis of TF+MPs in T1DM patients and healthy controls. (a) total
TF+MPs; (b) TF+PMPs; (c) TF+RMPs; (d) TF+TMPs; (e) TF+BMPs; (f) TF+MMPs and (g) TF+EMPs. (C) The ratio of TF+MPs and PS+MPs (TF+MPs/PS+MPs) in T1DM patients
and healthy controls. (a). TF+PS+MPs/PS+MPs; (b) TF+PS+PMPs/PS+PMPs; (c) TF+ PS+RMPs/PS+RMPs; (d) TF+PS+TMPs/PS+TMPs; (e) TF+PS+BMPs/PS+BMPs; (f) TF+PS+MMPs/
PS+MMPs and (g) TF+PS+EMPs/PS+EMPs. Data are expressed as MPs counts per microliter of PFP.
Abbreviations: PS, phosphatidylserine; MPs, microparticles; PMPs, platelet-derived MPs; TF, tissue factor; RMPs, red blood cell-derived MPs; TMPs, T lymphocytes-derived
MPs; BMPs, B lymphocytes-derived MPs; MMPs, monocytes-derived MPs; EMPs, endothelium-derived MPs.
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Correlations of MPs with Clinical
Parameters in Patients with T1DM
The correlative analyses showed limited signiﬁcant asso-
ciations with the PS+MPs or TF+PS+MPs, expect some
isolated ﬁndings (Supplementary Tables 1–7).
Discussion
Our study suggests that the circulating procoagulant
PS+MPs and those derived from platelets, lymphocytes
and endothelium, as well as their TF expressing forms,
were elevated in patients with T1DM compared to healthy
controls. To our knowledge, this is the ﬁrst study investi-
gating the TF+PS+MPs in T1DM patients.
TF is a procoagulant protein expressed constitutively on
themembrane ofmost non-vascular cells and expressed induc-
tively on monocytes and endothelial cells.33,34 The expression
of functional TF on MPs could signiﬁcantly enhance their
procoagulant activity in addition to PS.26,35–37 A recent study
suggested that the TF+ and PS+MPswere associatedwithmeal
intake, and lipid-lowering agents in T1DM patients.38 In our
study, the elevated counts of TF+MPs in patients with T1DM,
mostly derived from platelet, lymphocytes and endothelial
cells, suggested a hypercoagulable state of T1DM patients.39
TF+PS+MP count was higher in patients with established
microvascular complications without an obvious signal of its
subgroup. It suggests TF+PS+MP may reﬂect overall damage
of the blood components including circulating cells and epithe-
lium.We also observed elevated TF+PS+PMP count in patients
with higher HbA1c. It is partially because the platelet contri-
butes to the highest count of MPs in the circulation, and also
suggests that platelet and TF may be more sensitive to hyper-
glycemia compared with other blood cells.40,41
Our results of the PS+MPs were in line with previous
studies.18,23 Sabatier et al18 suggested the PS+MPs,
PS+PMPs and PS+EMPs increased in patients with
T1DM, while only PS+MPs increased in patients with
type 2 diabetes. Salem et al23 showed an elevation of
PS+PMPs in patients with T1DM, especially those with
microalbuminuria or other complications, and suggested
the PS+PMPs could be a biomarker of microvascular com-
plications in T1DM patients. Bergen et al42 reported an
elevation of total unlabeled MPs and PS+MPs in T1DM
patients, especially in patients with microvascular compli-
cations. Our study further suggested the TF+ subsets of
total PS+MPs, PS+PMPs and PS+EMPs were also elevated
in the patients with T1DM, and may be potential biomar-
kers of the disease and its complications. The strength of
MPs and TF+MPs as biomarkers of T1DM is that they are
not strongly confounding with traditional risk factors of
diabetes as suggested in our study. However, more studies
with larger sample size and different controls are needed
before their clinical application.
Table 2 Sub-Analysis of PS+MPs and TF+PS+MPs in T1DM Patients According to Glucose Control and DR. Data are Presented as
Mean ± SDs
Variable (Counts/μL) DR HbA1c
with DR (n = 16) Without DR (n = 20) P value HbA1c >7
(n = 22)
HbA1c ≤ 7
(n = 14)
P value
PS+MPs 1041.27 ± 151.26 1108.29 ± 160.83 0.211 1081.75 ± 164.51 1072.03 ± 151.16 0.893
TF+MPs 236.17 ± 29.24 174.85 ± 41.44 <0.001 197.54 ± 44.91 211.22 ± 53.09 0.365
PMPs 393.53 ± 57.59 422.22 ± 44.54 0.101 406.45 ± 51.89 415.50 ± 54.08 0.615
TF+PMPs 60.55 ± 16.78 53.73 ± 15.00 0.207 64.03 ± 14.40 42.24 ± 5.57 <0.001
RMPs 69.15 ± 9.60 69.87 ± 9.73 0.825 68.93 ± 10.14 70.78 ± 8.48 0.590
TF+RMPs 9.76 ± 2.26 10.76 ± 3.37 0.317 10.50 ± 2.96 9.94 ± 2.97 0.599
TMPs 40.81 ± 7.78 39.16 ± 6.79 0.500 40.41 ± 7.87 38.87 ± 5.78 0.552
TF+TMPs 6.19 ± 2.45 7.19 ± 3.06 0.295 6.91 ± 2.93 6.40 ± 2.66 0.611
BMPs 14.98 ± 3.74 16.62 ± 3.35 0.175 15.84 ± 3.66 15.99 ± 3.53 0.907
TF+BMPs 2.43 ± 1.35 2.77 ± 1.16 0.427 2.79 ± 1.29 2.29 ± 1.13 0.263
MMP 66.88 ± 8.26 71.01 ± 11.14 0.225 70.89 ± 9.80 65.74 ± 10.06 0.150
TF+MMP 16.60 ± 3.84 18.87 ± 4.69 0.128 18.20 ± 5.09 17.18 ± 2.73 0.519
EMPs 2.24 ± 1.49 2.65 ± 1.68 0.452 2.44 ± 1.53 2.52 ± 1.76 0.886
TF+EMPs 0.98 ± 0.73 0.91 ± 0.53 0.749 0.99 ± 0.67 0.84 ± 0.50 0.510
Abbreviations: T1DM, type 1 diabetes mellitus; DR, diabetic retinopathy; HbA1c, glycated hemoglobin; PS, phosphatidylserine; MPs, microparticles; PMPs, platelet-derived
MPs; TF, tissue factor; RMPs, red blood cell-derived MPs; TMPs, T lymphocytes-derived MPs; BMPs, B lymphocytes-derived MPs; MMPs, monocytes-derived MPs; EMPs,
endothelium-derived MPs.
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EMP is a small portion of the circulating PS+MPs, asso-
ciating with functional status and stability of endothelial cell.43
Multiple in vivo and in vitro studies showed the EMPs con-
tribute to coagulation, angiogenesis, vertebral capillary
damage and other vascular effects. Increased EMP levels
were found in several pathological conditions such as hyper-
tension, dyslipidemia, atherosclerosis, metabolic syndrome
and coronary artery disease.8,11,44–47 Sabatier et al18 have
shown that the levels of EMPs were elevated in T1DM and
associated with microvascular complications, suggesting that
EMPs could be a marker of diabetes-related vascular disease.
However, our results did not show an obvious elevation of
EMP level in patients withDR. It could be becausemost of our
patients with DR had only mild or moderate nonproliferative
DR but only one patient was identiﬁed with proliferative DR.
And we did not identify other microvascular complications or
cardiovascular co-morbidities among our patients.
This study presents some limitations. In this study, we use
the immunological method to detect PS+MPs levels using
speciﬁc ﬂuorescence antibodies, but this method could not
provide information about whether the TF+PS+MPs are func-
tionally active. Besides, Our study was designed as a case-
control study with limited sample size. We cannot conclude
the causation or the pathophysiological link between the
procoagulant MPs and the phenotypes. The results require
validation in other ethnic populations.
In conclusion, we show that TF+PS+MPs from differ-
ent origins increased in patients with T1DM. It indicated
an abnormal procoagulant status in the T1DM patients.
They may be potentially used as biomarkers of T1DM
and its complications after further exploration and conﬁr-
mation, and support investigation of the development of
TF+MPs from different origins in the hyperglycemia
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